Table 3.

Toxicity

Adverse event	Grade	Continued bevacizumab (n = 23)	Ceased bevacizumab (n = 24*)
Anemia	All grades	1 (4%)	3 (13%)
	Grade ≥3	0 (0%)	0 (0%)
Febrile neutropenia	All grades	0 (0%)	0 (0%)
	Grade ≥3	0 (0%)	0 (0%)
Neutropenia (without fever)	All grades	3 (13%)	2 (8%)
	Grade ≥3	1 (4%)	1 (4%)
Thrombocytopenia	All grades	7 (30%)	2 (8%)
	Grade ≥3	2 (9%)	1 (4%)
Nausea and vomiting	All grades	7 (30%)	8 (33%)
	Grade ≥3	1 (4%)	0 (0%)
Diarrhoea	All grades	3 (13%)	0 (0%)
	Grade ≥3	0 (0%)	0 (0%)
Constipation	All grades	6 (26%)	4 (17%)
	Grade ≥3	0 (0%)	0 (0%)
Fatigue	All grades	20 (87%)	13 (54%)
	Grade ≥3	2 (9%)	3 (13%)
Central nervous system hemorrhage	All grades	1 (4%)	0 (0%)
	Grade ≥3	0 (0%)	0 (0%)
Bleeding	All grades	3 (13%)	1 (4%)
	Grade ≥3	0 (0%)	0 (0%)
Deep-vein thrombosis	All grades	1 (4%)	0 (0%)
	Grade ≥3	0 (0%)	0 (0%)
Proteinuria	All grades	1 (4%)	0 (0%)
	Grade ≥3	0	0
Hypertension	All grades	19 (83%)	17 (71%)
	Grade ≥3	1 (4%)	0
Abscess	All grades	1 (4%)	0
	Grade >=3	0	0

* One patient declined to participate after randomization and no further toxicity data are available.